PreciseDx

PreciseDx is an AI-driven pathology company focused on improving breast cancer outcomes. They offer a platform that provides patient-specific risk information through the analysis of morphology features, enabling more personalized treatment plans. Their platform leverages deep insights derived from their digital health platform to transform and standardize both diagnosis and clinical management of cancer. They are dedicated to democratizing access to high-quality medical care and information, regardless of location.

PreciseDx is led by a team of experts in pathology, diagnostics, technology, and business. They have secured $20.7 Million in Series B funding and have partnerships with leading companies like Agilent, IBM, and Merck. Their AI-powered predictive platform creates disease-specific assays that deliver new levels of patient risk information to drive benefits across the healthcare continuum. They are committed to research and development, with several publications in notable journals like BMC and Clinical Breast Cancer, showcasing the effectiveness of their platform.

PreciseDx is a company dedicated to improving patient outcomes by democratizing access to high-quality medical care and information. They achieve this by providing AI-powered diagnostic solutions that offer objective, quantitative, and accurate risk assessment information. The company focuses on transforming clinical diagnosis and patient management in areas like breast cancer, prostate cancer, and Parkinson's disease, enabling better treatment plans and personalized care for patients worldwide.

PreciseDx fosters a culture of innovation, collaboration, and dedication to improving patient outcomes. The company leverages cutting-edge technology like artificial intelligence and prioritizes research and development, creating a dynamic and intellectually stimulating environment. The leadership team, composed of experts in pathology, diagnostics, technology, and business, emphasizes a collaborative approach and the importance of diverse perspectives. This culture of high-performance and collective achievement is reflected in their commitment to developing and deploying AI-powered solutions that benefit both patients and healthcare professionals.

PreciseDx, with its focus on democratizing access to high-quality medical care and information, values diversity, equity, and inclusion across its team and operations. This commitment is evident in its mission to improve patient outcomes by transforming clinical diagnosis and patient management, regardless of location or background. The company highlights its diverse leadership team with expertise in pathology, diagnostics, technology, and business. They also demonstrate a commitment to diversity through their engagement with organizations like the National Comprehensive Cancer Network (NCCN) and their participation in events like the FLASCO Oncology Business Summit, which fosters collaboration among oncology leaders.